Special Issue

Ophthalmic Pharmacology

Message from the Guest Editor

For various ophthalmic diseases, the current treatment mainly involves eyedrops and intraocular/periocular injections. However, recent advances in the development of novel therapeutic agents involves gene therapy utilizing viral vectors, stem cell therapies and miRNAs targeting different signaling pathways, which may be also applicable to ophthalmic pharmacological research. This Special Issue will provide new concepts, regimens and drugs for the treatment of various eye diseases, including retinal disorders, glaucoma and other optic neuropathies, as well as ocular surface disorders. We are looking forward to your valuable contribution to this Special Issue.

Guest Editor

Dr. Si Hyung Lee

Department of Ophthalmology, Soonchunhyang University Hospital Bucheon, Bucheon 170, Republic of Korea

Deadline for manuscript submissions

closed (6 August 2024)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/194485

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

